Target-Mediated Drug Disposition Population Pharmacokinetics Model of Alirocumab in Healthy Volunteers and Patients: Pooled Analysis of Randomized Phase I/II/III Studies by Djebli, Nassim et al.
HAL Id: hal-02309820
https://hal.archives-ouvertes.fr/hal-02309820
Submitted on 9 Oct 2019
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d’enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
Target-Mediated Drug Disposition Population
Pharmacokinetics Model of Alirocumab in Healthy
Volunteers and Patients: Pooled Analysis of
Randomized Phase I/II/III Studies
Nassim Djebli, Jean-Marie Martinez, Laura Lohan, Sonia Khier, Aurélie
Brunet, Fabrice Hurbin, David Fabre
To cite this version:
Nassim Djebli, Jean-Marie Martinez, Laura Lohan, Sonia Khier, Aurélie Brunet, et al.. Target-
Mediated Drug Disposition Population Pharmacokinetics Model of Alirocumab in Healthy Volunteers
and Patients: Pooled Analysis of Randomized Phase I/II/III Studies. Clinical Pharmacokinetics,
Springer Verlag, 2017, 56 (10), pp.1155-1171. ￿10.1007/s40262-016-0505-1￿. ￿hal-02309820￿
ORIGINAL RESEARCH ARTICLE
Target-Mediated Drug Disposition Population Pharmacokinetics
Model of Alirocumab in Healthy Volunteers and Patients: Pooled
Analysis of Randomized Phase I/II/III Studies
Nassim Djebli1 • Jean-Marie Martinez1 • Laura Lohan2 • Sonia Khier2,3,4,5 •
Aure´lie Brunet1 • Fabrice Hurbin1 • David Fabre1
 The Author(s) 2017. This article is published with open access at Springerlink.com
Abstract
Background and Objective Proprotein convertase subtil-
isin/kexin type 9 inhibition with monoclonal antibodies
such as alirocumab significantly reduces low-density
lipoprotein-cholesterol levels ± other lipid-lowering ther-
apies. We aimed to develop and qualify a population
pharmacokinetics (PopPK) model for alirocumab in heal-
thy subjects and patients, taking into account the mecha-
nistic target-mediated drug disposition (TMDD) process.
Methods This TMDD model was developed using a subset
of the alirocumab clinical trial database, including nine
phase I/II/III studies (n = 527); the model was subse-
quently expanded to a larger data set of 13 studies
(n = 2870). Potential model parameters and covariate
relationships were explored, and predictive ability was
qualified using a visual predictive check.
Results The TMDD model was built using the quasi-
steady-state approximation. The final TMDD–quasi-
steady-state model included a significant relationship
between distribution volume of the central compartment
and disease state: distribution volume of the central com-
partment was 1.56-fold higher in patients vs. healthy sub-
jects. Separately, application of the model to the expanded
data set revealed a significant relationship between linear
clearance and statin co-administration: linear clearance was
1.27-fold higher with statins. The good predictive perfor-
mance of the TMDD model was assessed based on
graphical and numerical quality criteria, together with the
visual predictive check and comparison of the predictions
to those from a PopPK model with parallel linear and
Michaelis–Menten clearances (i.e., simplification of the
TMDD PopPK model).
Conclusions This mechanistic TMDD PopPK model inte-
grates the interaction of alirocumab with its target and
accurately predicts both alirocumab and total proprotein
convertase subtilisin/kexin type 9 concentrations in healthy
subjects and patients.
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Key Points
The two-compartment, target-mediated drug
disposition–quasi-steady-state (TMDD–QSS)
population pharmacokinetics model of alirocumab
accurately predicted both drug and target
concentrations in 527 healthy volunteers or patients
from nine phase I/II/III clinical studies.
The final TMDD–QSS population pharmacokinetics
model included only one covariate: the disease state
(healthy subjects or patients) on the distribution
volume of the central compartment.
Successful application of the TMDD–QSS model on
an expanded data set of 2870 subjects/patients from
13 clinical studies revealed a significant relationship
between statin co-administration and linear
clearance; this is the first published TMDD model
developed on such a large population.
1 Introduction
Proprotein convertase subtilisin/kexin type 9 (PCSK9), a
major regulator of plasma low-density lipoprotein-choles-
terol (LDL-C) metabolism, has received considerable
attention in the last decade as a promising therapeutic
target in the management of lipid disorders and the pre-
vention of coronary heart disease [1–3]. In humans, PCSK9
is highly expressed in the liver, and to a lesser extent in the
small intestine and kidneys [4, 5]. As shown in Fig. 1,
secreted PCSK9 binds the LDL receptor (LDLR) on the
surface of the hepatocyte, leading to its internalization,
intracellular retention, and degradation in the lysosomes.
PCSK9 secretion therefore prevents the receptor from
being recycled to the plasma membrane for further clearing
of LDL-C [2, 6], resulting in a decrease of LDLR on the
cell surface of hepatocytes, which decreases the ability of
the liver to remove LDL-C from circulation and causes
higher levels of circulating LDL-C [2]. Human genetic
studies have shown that gain-of-function PCSK9 mutations
are associated with higher serum levels of LDL-C and
premature incidences of coronary heart disease, whereas
loss-of-function mutations are associated with low serum
levels of LDL-C and reduced risk of coronary heart disease
[7–10]. The complete loss of PCSK9 in humans has been
shown to result in the low serum LDL-C concentration of
about 15 mg/dL in healthy subjects [11, 12]. Inhibition of
PCSK9 therefore offers a novel therapeutic mechanism for
the lowering of LDL-C levels [13].
Monoclonal antibodies that exclusively target circulat-
ing PCSK9 prevent the association of PCSK9 with LDLR,
thereby promoting LDL-C clearance and LDLR recycling
back to the plasma membrane [2]. Alirocumab, one such
monoclonal antibody recently approved by the US Food
and Drug Administration and the European Medicines
Agency, has been shown to significantly reduce LDL-C
levels both alone and in combination with other lipid-
lowering therapies in heterozygous familial hypercholes-
terolemia (FH) and non-FH dyslipidemic individuals
[14–27].
The pharmacokinetics (PK) and pharmacodynamics of
alirocumab are well characterized [28–30]. The high
specificity of monoclonal antibodies to bind to a specific
target and subsequent turnover of the drug–target complex
can significantly impact the disposition of these drugs. This
target-mediated drug disposition (TMDD) model was first
described by Mager and Jusko in 2001 [31] and is shown in
Fig. 2. Monoclonal antibodies such as alirocumab that
exhibit TMDD are predominantly characterized by non-
linear PK at low concentrations owing to the saturability of
the target (as there are finite numbers of the target on the
cell surface), resulting in faster than linear elimination of
the drug. At high concentrations when the nonlinear target-
mediated elimination pathway is saturated, linear clearance
of alirocumab becomes more important, mostly because of
catabolism.
In this analysis (performed as part of the Biologics
License Application to the US Food and Drug Adminis-
tration for alirocumab), we aimed to develop and qualify a
population PK (PopPK) model for alirocumab, taking into
account the mechanistic TMDD process, by integrating all
of the information regarding the target (PCSK9) and the
alirocumab–PCSK9 complex. Potential relationships
between model parameters and demographic covariates,
relevant co-administration, antibody drug status, disease
state, administration site and device, and relevant biologic
constants were explored.
2 Methods
2.1 Clinical Studies and Sample Analysis
This TMDD model was developed on a subset of the
alirocumab clinical trial program database, including 527
healthy volunteers or patients from nine phase I/II/III
studies [32–39]. Subsequently, the model was expanded to
a larger data set (2870 subjects/patients from 13 studies)
[15, 16, 18, 19, 24]. The doses, dosing regimens, and main
characteristics of these clinical studies are presented in
Table 1. The protocols were approved by the relevant
N. Djebli et al.
ethics committees, and written informed consent was
obtained from all participants.
Total alirocumab, total PCSK9, and free PCSK9 con-
centrations in serum samples were determined using an
enzyme-linked immunosorbent assay; the upper and lower
limit of quantification (ULOQ and LLOQ, respectively) for
each of these parameters in the human serum matrix, and
their corresponding values in undiluted human serum, are
summarized in Table 2. Total PCSK9 concentrations were
determined following an acid treatment of the serum
samples that resulted in the dissociation of any complexed
PCSK9 (including any PCSK9–alirocumab complexes),
thereby permitting the quantification of all PCSK9 in the
sample. To assess immunogenicity, the presence of anti-
drug antibodies (ADAs, i.e., anti-alirocumab antibodies)
was evaluated using a validated, non-quantitative, titer-
based, bridging immunoassay at three different points:
during the initial screen, the confirmation assay for drug
specificity, and the assay in the serum samples. Parameters
used for assay sensitivity and drug tolerance limits are
summarized in Table 2.
2.2 Pharmacokinetic Exclusion Criteria
From the randomized and treated individuals, patients/sub-
jects receiving placebo treatment were excluded. From the
remaining patients/subjects receiving alirocumab, data were
excluded from the database for any of the following reasons:
missing observations, missing alirocumab concentrations,
missing total PCSK9 concentrations, or values below the
Fig. 2 General pharmacokinetic model of target-mediated drug
disposition (adapted from Mager and Krzyzanski [48]). First
described by Mager and Jusko in 2001 [31], this schematic shows
the drug in the central compartment (C) binds to free receptors (R) at
the second-order rate (Kon) to form a drug–receptor complex (RC).
This complex may then either dissociate at the first-order rate (Koff),
or be internalized via endocytosis and degraded at the first-order rate
(Kint). Free drug can also be eliminated from the system at the first-
order rate (Kel), or distributed to non-specific tissue-binding sites (AT)
at first-order rates Ktp and Kpt. The zero-order rate of synthesis (Ksyn)
and the first-order rate of degradation (Kdeg) of the free receptor, as
well as the input rate [In(t)] to the free drug compartment, are also
reflected. Free drug C, free receptor R, and the drug–receptor complex
RC are expressed in molar concentrations, and AT denotes moles of
nonspecifically tissue bound or distributed drug
Fig. 1 Mechanism of action of alirocumab, a PCSK9 inhibitor
(adapted from Lambert et al. [2]). ASO antisense oligonucleotides,
LDL low-density lipoprotein, LDLR LDL receptor, PCSK9 proprotein
convertase subtilisin/kexin type 9, siRNA small interfering RNA,
SREBP2 sterol-responsive element-binding protein 2
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LLOQ. Missing covariate values were replaced by the pre-
vious values from the same individual or interpolated if time
dependent. Completely missing covariate values (if not
resolved) led to the exclusion of the patient/subject. Missing
ADA status was not replaced with previous values but was
always considered as missing; all baseline values for ADAs
were set to a negative ADA status. For baseline values (e.g.,
baseline free and total PCSK9 concentrations), the mean was
calculated based on the available data before the first dose
administration.
2.3 TMDD Modeling
The TMDD PopPK analysis was performed with nonlinear
mixed-effects modeling (NONMEM) (ICON, Dublin, Ire-
land) software version 7.2 running on a LINUX cluster of
multi-processor computers. The first-order conditional
estimation with interaction option method was used for
each step of the model development, including the detec-
tion of outliers in the preliminary model.
2.3.1 Preliminary and Pharmacostatistical Model
Development
An outlier screening was performed using a preliminary
model. The best preliminary model was chosen based on
the examination of the objective function value (OFV),
parameter precision, error estimates, shrinkage values, and
the visual inspection of the goodness-of-fit plots. Following
outlier screening and deletion, the pharmacostatistical
model was developed based on the same criteria as the
preliminary model selection. The population parameters
(fixed effects and random effects) together with the indi-
vidual estimates were computed assuming no dependency
between model parameters and covariates.
2.3.2 Covariate Model Development
Demographic characteristics such as age, sex, race, body
weight, body mass index, disease state (DISST, healthy
subjects vs. patients), and albumin levels were tested as
potential model covariates. Other covariates included the
type of disease (FH vs. non-FH), baseline free and total
PCSK9 levels, ADA levels, and co-administration of
other anti-hypercholesterolemia drugs (fibrates, ezetimibe,
rosuvastatin, atorvastatin, or simvastatin). Unless other-
wise stated, time-varying values of covariates during the
course of the trial, in addition to baseline values, were
used.
Selected covariates were added individually to the
model (forward selection method) and tested for statistical
significance using the likelihood ratio test. The impact of
the covariate inclusion in the model on the quality of
individual fit was evaluated by visual inspection of the
goodness-of-fit plots [conditional weighted residuals
(CWRES) or individual weighted residuals (IWRES),
population predicted (PRED) or individual predicted
(IPRED) in comparison with observed concentrations
(OBS)] before and after covariate inclusion. The covariates
that produced significant changes (p\ 0.05) in the OFV
(DOFV of C3.84 units) were retained in the model. To
verify that the covariates selected during the model
building process were still relevant for the final population
model, each term of the proposed final model was alter-
natively deleted (backward deletion), and its impact on the
OFV was determined; covariates that decreased OFV by
less than 10.8 (p = 0.001) would be excluded. Before
qualification, model verification was performed by exam-
ination of the goodness-of-fit plots and by estimation of
several quality criteria (mean prediction error, precision,
and average fold error).
Table 2 Summary of bioanalysis assay characteristics for total alirocumab, total and free PCSK9 concentrations (measured by ELISA in human
serum), and detection of ADAs at three different evaluations per serum sample
Concentration in 9 % human serum matrix (ng/mL) Concentration
in undiluted
human serum
(lg/mL)
Sample x ULOQ LLOQ ULOQ LLOQ
Total alirocumab 2% 100 1.56 5 0.078
Total PCSK9 2% 200 3.13 10 0.156
Free PCSK9 50% 1000 15.63 2 0.031
ADAs Initial screening Immunogenicity assay
sensitivity
Drug tolerance (for 500 ng/mL of positive
control)
Phase I and II
studies
Positive/negative
titer
1.7 ng/mL 329 lg/mL
Phase III studies 5.6 ng/mL 191 lg/mL
ADAs anti-drug antibodies, AR analytical recovery, CV coefficient of variation, ELISA enzyme-linked immunosorbent assay, LLOQ lower limit
of quantification, PCSK9 proprotein convertase subtilisin/kexin type 9, ULOQ upper limit of quantification
TMDD Model of Alirocumab in Healthy Volunteers and Patients
2.3.3 Qualification of the Model
The qualification of the predictive performance of the
TMDD PopPK model was performed by examination of the
goodness-of-fit plots, visual predictive check (VPC), and
comparison of the predictions to those from a PopPK model
with parallel linear and Michaelis–Menten clearances (a
simplification of the current TMDD PopPK model).
To evaluate the impact of the removal of concentration
time points after outliers’ detection, the final PopPK model
was applied to the whole data set.
2.3.4 Application and Refinement of the TMDD Model
to the Expanded Data Set
The expanded application of the developed model to the
data set of 2870 healthy subjects and patients from 13
clinical studies allowed for the qualification of the previ-
ously mentioned assumptions on a much larger data set.
Covariate screening was performed using the same
approach, and the same criteria described above were used
to select the pharmacostatistical model, the parameter–co-
variate relationships, and the final TMDD PopPK model
with the expanded data set. Similarly, the model qualifi-
cation was based on the goodness-of-fit plots, the compu-
tation of numerical quality criteria for both total
alirocumab and total PCSK9, and the VPC method.
3 Results
3.1 Summary of Patient/Subject Characteristics
Descriptive statistics (baseline values) of potential covari-
ates of the patients/subjects tested in the TMDD analysis
are summarized in Table 3.
3.2 Pharmacostatistical Model Development
Based on the mechanism of action of alirocumab, the
available clinical data, and the known quasi-instantaneous
alirocumab–PCSK9 complex formation, a TMDD PopPK
model with the quasi-steady-state (QSS) approximation
was deemed to be the most appropriate model to describe
the PK of alirocumab. The pharmacostatistical model was a
TMDD–QSS PopPK model, occurring in the central com-
partment of a two-compartment model: the central com-
partment (Vc, L) and the peripheral compartment (Vp, L);
the two compartments were linked by an inter-compart-
mental clearance (Q, L/day). The QSS approximation was
parameterized by the association rate constant Kon
(nM-1day-1), the PCSK9 degradation rate constant (Kdeg,
day-1), and the complex internalization rate constant (Kint,
day-1). In addition, a linear clearance (CLL, L/day) from
the central compartment, representing the catabolic clear-
ance, was also parameterized. To describe the absorption
process, a first-order absorption rate constant from the
depot to the central compartment (Ka, day
-1) with a lag-
time (LAG, day) and the bioavailability (F1) were esti-
mated for subcutaneous administration. These variables
composed the fixed-effects model parameters.
Other approximations of the TMDD model are
explained in detail in Fig. 3. The quasi-equilibrium
approximation was ruled out owing to the long elimination
half-life of the alirocumab–PCSK9 complex (i.e., non-
negligible Kint). The irreversible binding approximation
was also ruled out, given that the KD was measured in vitro
to be about 0.58 nM. The QSSconst simplification was not
made, given that the total PCSK9 was not constant, and the
Michaelis–Menten approximation and Michaelis–Menten
equation simplifications were not made, given that the
alirocumab–PCSK9 complex concentration is not much
smaller compared with free alirocumab.
The inter-individual error term was evaluated for all
fixed-effect parameters (including CLL, Kint, Kdeg, Q, Vc,
Ka, and F1) except Kon and Vp, which were fixed to a
constant value following sensitivity analysis.
A preliminary TMDD PopPK model was developed for
outliers’ detection and deletion. However, because of the
good quality of both the model and the data set, the out-
liers’ deletion step did not need to be performed. No
combination (among 56 tested) of estimated covariance
between the seven estimated inter-individual variabilities
(within an x-block) improved the quality of the model.
The PopPK parameters obtained before covariate
inclusion are presented in Table 4. As shown in Table 4,
the relative standard errors of the estimates for each
parameter were small enough so that the 95% confidence
interval did not include zero. The maximum values of
7.08% for the fixed-effect parameters and 27.1% for the
random-effect parameters confirmed the quality of the
model.
Supplementary Table 1 summarizes the main quality
criteria computed for the comparison of PRED and IPRED
vs. OBS (the dependent variable in NONMEM) for the
pharmacostatistical model for the pool of total alirocumab
and total PCSK9, as well as for each of these dependent
variables individually. The mean prediction errors for
PRED vs. OBS and IPRED vs. OBS were slightly but
significantly different from zero. The average fold error of
the pool, total alirocumab, and total PCSK9 was 1.61, 1.94,
and 1.37, respectively, for PRED vs. OBS, and 1.24, 1.28,
and 1.21, respectively, for IPRED vs. OBS. In addition,
among 9379 samples, only 11 |IWRES| and 0 |CWRES|
values were higher than 8, and only 15 IWRES and 17
CWRES were out of the range [-4; ?4]. Based on these
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numerical quality criteria, the model quality was found to
be good for the pool of total alirocumab and total PCSK9.
For each of these dependent variables separately, the
quality of model estimation obtained for total PCSK9 was
found to be slightly better than that of total alirocumab.
3.3 Screening and Selection of Covariates
Each significant covariate (listed in Table 3) was added
sequentially (univariate model) and the developed model
was evaluated for its effect on OFV, 95% CI, and inter-
individual variability of the corresponding parameter esti-
mates. Only one significant parameter–covariate relation-
ship was retained: DISST on Vc. The DOFV was found to
be -88.4 according to the following equation:
Vc ¼ TVVC  COV1DISST;
where TVVC is the typical value of Vc, COV1 is the DISST
effect on Vc, and DISST = 0 for healthy subjects and 1 for
patients.
In the last step in the covariate model development, the
relevance of the covariates selected during the model
building process in the final population model was verified
by performing backward deletion; as previously men-
tioned, covariates that decreased OFV by less than 10.8
(p = 0.001) would be excluded. However, because the
DISST-Vc relationship led to a decrease of 88.4 of the
OFV, it was retained in the final model.
3.4 Final Population Model
The final TMDD PopPK parameters are presented in
Table 4 alongside those for the pharmacostatistical model.
As previously mentioned, the final model included only
Table 3 Descriptive statistics of the demographic characteristics (baseline values) of the patients/subjects included in the initial data set
(n = 527) and the expanded data set (n = 2870)
Patient characteristics Initial data set (n = 527) Expanded data set (n = 2870)
Age, years; mean (SD) 52.5 (13.0) 58.2 (11.7)
Sex, male/female; n (%) 280 (53.1)/247 (46.9) 1781 (62.1)/1089 (37.9)
Race, Caucasians/Blacks/Asians/others; n (%) 433 (82.2)/63 (12.0)/25 (4.74)/6 (1.14) 2502 (87.2)/137 (4.77)/144 (5.02)/87 (3.03)
Type of disease, FH/non-FH; n (%) 158 (30.0)/369 (70.0) 817 (28.5)/2053 (71.5)
Disease state, patients/healthy subjects; n (%) 377 (71.5)/150 (28.5) 2720 (94.8)/150 (5.23)
Body weight, kg; mean (SD) 80.6 (16.4) 85.0 (18.4)
BMI, kg/m2; mean (SD) 28.0 (4.60) 29.5 (5.40)
Co-medication, yes/no; n (%)
Alirocumab monotherapya 157 (29.8)/370 (70.2) 158 (5.51)/2712 (94.5)
Ezetimibe 68 (12.9)/459 (87.1) 465 (16.2)/2405 (83.8)
Any fibrate 25 (4.74)/502 (95.3) 138 (4.81)/2732 (95.2)
Any statin 321 (60.9)/206 (39.1) 2662 (92.8)/208 (7.25)
Low-dose statinb 203 (38.5)/324 (61.5) 1335 (46.5)/1535 (53.5)
High-dose statinc 118 (22.4)/409 (77.6) 1359 (47.4)/1511 (52.6)
Abdomen as preferred alirocumab injection site, yes/
no; n (%)
469 (89.0)/58 (11.0) 2183 (76.1)/687 (23.9)
Baseline serum levels; mean (SD)
Creatinine clearance, mL/min 109 (30.4) 101 (33.7)
Glomerular filtration rate, mL/min 94.1 (21.1) 83.7 (20.3)
Albumin, g/L 43.8 (2.91) 41.7 (3.33)
Baseline total PCSK9 concentration, nM 7.66 (3.06) 9.14 (6.84)
Baseline free PCSK9 concentration, nM 2.55 (1.07) 3.49 (1.53)
Time-varying free PCSK9 concentration, nM 1.25 (1.38) 1.07 (1.42)
Absence of ADAs during study (ADAMAX),
true/false; n (%)
139 (26.4)/388 (73.6) 314 (10.9)/2556 (89.1)
ADAs anti-drug antibodies, BMI body mass index, FH familial hypercholesterolemia, PCSK9 proprotein convertase subtilisin/kexin type 9, SD
standard deviation
a Alirocumab could be combined with treatment with ezetimibe, a fibrate, or a statin
b Low-dose statins include co-administration of rosuvastatin\20 mg/day, atorvastatin\40 mg/day, or simvastatin (any dose)
c High-dose statins include co-administration of rosuvastatin C20 mg/day, or atorvastatin C40 mg/day
TMDD Model of Alirocumab in Healthy Volunteers and Patients
one significant parameter–covariate relationship: DISST–
Vc. The Vc was estimated to be 3.16 L for healthy subjects
and 4.93 L for patients. Therefore, Vc was estimated to be
1.56-fold higher in patients (n = 377) compared with
healthy subjects (n = 150), with a 17.4% decrease (from
37.3 to 30.8%) in the inter-subject variability. The highest
absolute value of the correlation between parameter esti-
mates (0.715) was lower than 0.95, and the %RSEs were
small enough so that 95% CIs did not include zero: the
highest %RSE value was 7.79% for the fixed-effect
parameters and 42.5% for the inter-individual error terms.
Supplementary Table 1 summarizes the main quality
criteria computed for the comparison of PRED and IPRED
vs. OBS for the final model alongside the pharmacostatis-
tical model. As shown in Supplementary Table 1, there
was a clear improvement in the model quality from the
pharmacostatistical model to the final model for all of the
dependent variables (pool, total alirocumab, total PCSK9).
The mean prediction error for all of the dependent variables
was low but significantly different from zero for both
PRED vs. OBS and IPRED vs. OBS. The mean prediction
errors of the mean observed value was 7.79 and 4.94% for
the pool, 7.50 and 2.96% for the total alirocumab con-
centrations, and 8.51 and 9.81% for the total PCSK9 con-
centrations for PRED vs. OBS and IPRED vs. OBS,
respectively. The average fold error was 1.56 and 1.24 for
the pool, 1.85 and 1.28 for the total alirocumab concen-
trations, and 1.34 and 1.21 for the total PCSK9 concen-
trations for PRED vs. OBS and IPRED vs. OBS,
respectively. The correlation characteristics for the pool
were excellent for both PRED and IPRED vs. OBS, as
shown by the correlation coefficients of greater than 0.96
(0.967 for PRED and 0.995 for IPRED). Based on these
numerical quality criteria, the model quality was found to
be good for the pool of total alirocumab and total PCSK9.
For each of these dependent variables separately, as above,
the quality of model estimation obtained for total PCSK9
was found to be slightly better than that of total alir-
ocumab. The CWRES vs. PRED and IWRES vs. IPRED
for the final model are plotted in Fig. 4. The PRED and
IPRED vs. OBS for the pool, for total alirocumab and for
total PCSK9 are plotted in Fig. 5 to evaluate the global
quality of the model fitting.
3.5 Model Qualification
VPCs were used to evaluate the performance of the final
model. The VPC of each study is presented for total alir-
ocumab in Supplementary Fig. 1 and for total PCSK9 in
Supplementary Fig. 2. The results of the VPC for both total
alirocumab and total PCSK9 showed that the overwhelm-
ing majority of the observed concentrations were included
in the 5th–95th percentile range, illustrating the good
qualification of the developed TMDD–QSS PopPK model.
As only one covariate was included in the final model
(DISST on Vc) and each study included either only healthy
subjects or patients, it was not necessary to compute and
plot the prediction-corrected VPC.
Simulations were performed to evaluate the impact of
DISST on Vc on total alirocumab, total PCSK9, and free
PCSK9 levels after treatment for up to 12 weeks with alir-
ocumab 75 mg every 2 weeks (Q2W; Fig. 6a) or alir-
ocumab 150 mg Q2W (Supplementary Fig. 3a). A summary
of the predicted exposures is also shown in Supplementary
Table 3. These simulations predicted a lower Area Under
the Curve between Week 10 and Week 12 (i.e. following the
6th Q2W administration) (AUCW10–W12) and maximum
plasma concentration (Cmax) for total alirocumab and total
PCSK9 after 75- and 150-mg Q2W administration in
patients compared with healthy volunteers. For free PCSK9
concentrations, the simulations predicted a 1.42-fold higher
AUCW10–W12 and a 1.09-fold higher Cmax after the 75-mg
Q2W dose in patients compared with healthy volunteers,
while a 2.89-fold higher AUCW10–W12 and a 3.62-fold
Fig. 3 Hierarchy of approximations of the target-mediated drug
disposition (TMDD) model (adapted from Gibiansky et al. [49]). The
first approximation of the general TMDD model, the quasi-equilib-
rium (QE), was suggested by Mager and Krzyzanski in 2005 [48]. The
quasi-equilibrium approximation assumes the internalization and
elimination rate constant (Kint) of the drug (C)–receptor (R) complex
(RC) is much smaller and negligible compared with the dissociation
rate constant (Koff); KD, the equilibrium dissociation constant, is the
ratio of Koff and the association rate constant of the complex (Kon).
Conversely, the irreversible binding (IB) approximation assumes that
Koff is much smaller than Kint. The quasi-steady-state (QSS)
approximation assumes that the binding process is nearly instanta-
neous, and the compound, target, and complex are in quasi-steady-
state (KSS). The Michaelis–Menten (MM) approximation assumes that
time derivatives of the free and total drug concentrations are similar,
which allows this approximation to describe the system when RC is
small relative to C. Further simplifications can be made to the quasi-
equilibrium (QEconst), QSS (QSSconst), and Michaelis–Menten
approximations/equations by assuming Rtot (R ? RC) is constant.
Kdeg rate of degradation, Ksyn rate of synthesis
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higher Cmax was predicted after the 150-mg Q2W dose; this
illustrates a more pronounced saturation of the TMDD
elimination in healthy volunteers compared with patients at
the higher alirocumab dose.
3.6 Post-Submission Analysis: TMDD–QSS Model
Expanded to 2870 Healthy Subjects/Patients
from 13 Studies
Descriptive statistics (baseline values) of potential covari-
ates of the patients/subjects tested in the TMDD analysis in
the expanded data set are summarized in Table 3, and the
obtained PopPK parameters are presented in Table 4. After
many attempts, the TMDD–QSS model converged with
very acceptable quality criteria (Supplementary Table 1).
The pharmacostatistical model with the expanded data set
included theory-based allometric scaling on CLL, Q, and
Vc (the Vp being fixed similarly to the previous TMDD–
QSS model), as previously described [40]. The body
weight (WT) was included on those parameters as follows:
Pi ¼ TVP WT=WTmedð ÞEXP;
where Pi is the individual parameter, TVP is the typical
value of the parameter, WTmed is the median value of body
weight in the expanded data set, and the exponent EXP
equals 1 for Vc and 0.75 for CLL and Q. The inter-pa-
tient/subject variability was estimated for seven model
parameters (CLL, Kint, Kdeg, Q, Vc, Ka, and F1) and ranged
between 22.7 and 85.0% in the expanded model. The
residual variability was moderate with a coefficient of
variation of 15.2% in the expanded model for the propor-
tional error term.
The final model of the expanded data set included one
significant relationship between statin co-administration
(STATIN) and CLL according to the following equation:
CLL ¼ TVCLL  COV1STATIN;
where TVCLL is the typical value of CLL, COV1 is the
STATIN effect on CLL, and STATIN = 1 with statin co-
administration and 0 without statin co-administration. The
CLL was estimated to be 0.176 L/day without statins and
0.224L/daywith statins (i.e., 1.27-fold higherCLLwith statin
co-administration). In addition, the comparison of the main
quality criteria reflecting the predictive performance of the
TMDD–QSS and TMDD–Michaelis–Menten models are
summarized in Supplementary Table 2. This comparison
highlights the very similar predictive performance of the two
models toward the prediction of total alirocumab concentra-
tions. The model was qualified using the VPC (see Fig. 7 for
alirocumab and Fig. 8 for total PCSK9, stratified by study).
As above, simulations were performed to evaluate the
impact of statin co-administration on CLL on total alir-
ocumab, total PCSK9, and free PCSK9 levels after
treatment for up to 12 weeks with alirocumab 75 mg Q2W
(Fig. 6b) or alirocumab 150 mg Q2W (Supplementary
Fig. 3b), and a summary of the predicted exposures are
also shown in Supplementary Table 3. These simulations
predicted a lower AUCW10–W12 and Cmax for total alir-
ocumab after 75- and 150-mg Q2W administration in
individuals with statin co-administration compared with
those without statin co-administration. For free PCSK9
concentrations, the simulations predicted a 2.08-fold higher
AUCW10–W12 and a 1.67-fold higher Cmax after the 75-mg
Q2W dose in individuals taking statins compared with
those not taking statins, while AUCW10–W12 and Cmax were
predicted to be 3.57-fold and 5.91-fold higher, respec-
tively, after the 150-mg Q2W dose, suggesting an ampli-
fied saturation of the TMDD elimination at the higher dose
in individuals without statin co-administration compared
with those taking statins.
4 Discussion
This TMDD PopPK analysis was first conducted in a data
set of 527 subjects and patients enrolled in nine phase I/II/
III studies, and subsequently on a larger data set of 2870
individuals in 13 studies. To our knowledge, this expanded
model is the first published TMDD model developed on
more than 1564 individuals [41]. The great benefit of
developing and qualifying a TMDD model is that it allows
the prediction of the PK of alirocumab, by integrating all
available information regarding the target (PCSK9) and
taking into account the mechanistic behavior of the system.
A TMDD PopPK model was developed with the QSS
approximation, occurring in the central compartment of a
two-compartment model (Vc and Vp) linked by an inter-
compartmental clearance (Q, L/day). The QSS approxi-
mation was parameterized by Kon, Kdeg, Kint, and CLL from
the central compartment (representing the catabolic clear-
ance). The absorption process was described by a first-
order Ka from the depot to the central compartment with a
LAG and F1 for subcutaneous administration.
The TMDD–QSS PopPK model developed in this
analysis accurately predicted both alirocumab and total
PCSK9 concentrations observed in patients and healthy
subjects. This was demonstrated at each step of the model
building process and, at the end, was assessed using the
VPC approach. The inter-individual variability was mod-
eled through an exponential error model and was estimated
for all parameters except LAG, Kon, and Vp (which were
fixed to a constant value). A combined (additive ? pro-
portional) error model was used to model the residual
variability. The available potential sources of variability on
the population parameters were extensively investigated.
Among all the covariates tested, only one significant
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parameter–covariate relationship was retained in the
TMDD–QSS PopPK model: the estimated typical value of
Vc was 3.16 L for healthy volunteers vs. 4.93 L for patients.
Of the demographic characteristics tested for effect on
the TMDD PopPK parameters (age, weight, body mass
index, sex, and race), none resulted in a significant
improvement of the model fit in the initial population of
527 subjects. Additionally, there was no relationship
between albuminemia, the presence of ADAs, the site of
injection, the baseline levels of total and free PCSK9, the
type of disease (FH vs. non-FH), co-medication (ezetimibe,
high-dose statin, low-dose statin), and the parameters of the
TMDD model in this population.
At first sight, the link between DISST and Vc seems
surprising. There is, however, a huge collinearity between
DISST and statin co-medication. In the data set including
527 individuals, 321/377 patients were co-administered
statins while only 56/377 patients and all of the 150 healthy
volunteers received alirocumab alone. At the first covariate
screening step, the links between DISST or statins and Vc
were very similar in terms of OFV decrease (DOFV\1
unit) with a similar impact on Vc: 3.16 L for healthy vol-
unteers vs. 4.93 L for patients and 4.13 L without statins vs.
6.73 L with statins. However, the model with inclusion of
statins seemed over-parameterized (conditional number of
22,333, given that a value higher than 1000 suggests an
over-parameterization of the model) and explained less
inter-individual variability on Vc compared with the model
with inclusion of the DISST (10.2 vs. 17.2%, respectively).
When looking at the empirical Bayesian estimates of the
final model (taking into account the relationship between
DISST and Vc), the median estimated Vc is 5.11 L for
patients undergoing statin therapy (n = 321), 4.23 L for
patients that were not taking statins (n = 56), and 3.17 L for
the healthy volunteers (n = 150). These figures, in addition
to the good quality criteria and predictive performance of
the model using numerical and graphical qualification,
strongly suggest that despite the huge collinearity between
the two covariates, the DISST provided the most relevant
information using the data set of the present analysis. Of
note, numerous covariates are often not included in such
mechanistic models, as the most important information is
provided by the second dependent variable (which, in this
case, is total PCSK9 concentrations).
Further to the Biologics License Application submis-
sion, this TMDD–QSS model was applied and refined on
an expanded data set of 13 clinical studies including 2870
individuals. The pharmacostatistical model and the corre-
sponding model parameters were very similar to those of
the TMDD–QSS model, except for the inclusion of theory-
based allometric scaling on CLL, Q, and Vc. The covariate
screening revealed only one significant relationship
between the CLL and statin co-administration, resulting in
a 1.27-fold higher CLL when statins were co-administered.
This finding is consistent with the considerable collinearity
suggested between DISST and statin co-administration in
the TMDD–QSS model with 527 individuals. Similar
observations were reported for evolocumab, another anti-
PCSK9 monoclonal antibody, where statins significantly
increased evolocumab clearance [42]. We propose two
hypotheses to explain these findings. The first relates to the
upregulation of PCSK9 by statins, as previously reported
[43, 44]. However, baseline PCSK9 concentrations, when
tested as a covariate, did not reveal a significant relation-
ship with any of the model parameters. The second
hypothesis is linked to previous findings that showed that
statins have pro-angiogenic effects, via the acceleration of
re-endothelialization and the mobilization of endothelial
Fig. 4 Relationship between a conditional (population) weighted residuals and population predicted concentrations and b individual weighted
residuals and individual predicted concentrations, for the pool after covariate inclusion. Linear scale. The tendency line is indicated in red
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progenitor cells [45, 46]. Indeed, the main catabolic path-
way for monoclonal antibodies representing the linear
clearance occurs via the reticuloendothelial system [47].
The pro-angiogenic effects of statins could thus result in a
significantly higher linear clearance.
bFig. 5 Relationship between population predicted and observed
concentrations (left panels), and between individual predicted and
observed concentrations (right panels) in the total data set after
covariate inclusion (linear scale) for the pool (a), total alirocumab
(b), and total proprotein convertase subtilisin/kexin type 9 (c). The
tendency line is indicated in red
Fig. 6 Predicted total alirocumab, total PCSK9, and free PCSK9
levels using the final model on alirocumab 75 mg Q2W for up to
weeks 10–12. a shows a typical healthy volunteer (red) vs. a typical
patient (blue) with the patient disease state (DISST) effect on Vc.
b shows the statin effect on CLL (with statin co-administration in blue
vs. without statin co-administration in red). CLL linear clearance,
PCSK9 proprotein convertase subtilisin/kexin type 9, Q2W every
2 weeks, Vc volume of distribution of central compartment
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The results of the simulations evaluating the impact of
these parameter–covariate relationships show, regardless of
the analyte (total alirocumab, total or free PCSK9, or
PCSK9–alirocumab complex), a notable DISST effect
(using the initial TMDD model), and to a lower extent, a
statin co-administration effect (using the final TMDD
model) on exposures. It is worth noting that healthy vol-
unteers represented 28.5% (150/527) in the initial data set,
vs. 5.23% (150/2870) in the expanded data set (i.e., more
than 94% of the expanded data set were patients). As
previously suggested, the predicted exposures were very
similar in patients using the initial TMDD model compared
with individuals with statin co-administration in the final
TMDD model, regardless of the alirocumab dose and the
analyte.
5 Conclusions
This model was well qualified using graphical and numer-
ical quality criteria and with the VPC approach. Therefore,
though the available free PCSK9 concentrations were not
used as a dependent variable in the present analysis (owing
to the application of the QSS approximation) and despite
the slight but significant mean prediction error values
observed in the numerical quality criteria, the mechanistic
Fig. 7 Visual predictive check results for total alirocumab
(n = 14097) per study (STUD) for the expanded data set. Linear
scale (observations, median, 5th and 95th percentiles, confidence
intervals of median and centiles). Dark blue dots indicate
observations; the solid red line is the median of observations; solid
dashed lines are the 5th and 95th percentiles of observations; pink and
blue areas are the confidence intervals of the median and 5th and 95th
percentiles of predictions
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model that was developed and qualified in the present
analysis correctly integrates the interaction of alirocumab
with its target PCSK9, and consequently well describes the
behavior of both alirocumab and PCSK9 kinetics.
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